Share this

Cancer Studies

The Cancer Network supports a wide range of clinical studies which are helping to progress cancer care in Scotland and beyond, and all Scottish research ongoing within the network is registered with the National Institute of Health Research (NIHR).

The cancer clinical trial portfolio is very dynamic and is frequently changing as studies open and close to recruitment. Across Scotland, there is a wide range of clinical trials happening in different disease sites. Information on trials happening in the UK can be found on the Be Part of Research platform and the Cancer Research UK website. For specific information on trials happening in Scotland please contact your cancer professional or your local cancer research network.

To highlight the clinical trials happening in Scotland the cancer research network will feature current trials happening during the different cancer awareness months that take place throughout the year.

 

   JULY: SARCOMA AND BONE CANCER AWARENESS MONTH

 

Sarcoma is a rare type of cancer that can either develop in the bones (bone cancer) or in the soft tissues of the body (soft tissue sarcoma). The soft tissues include the muscles, nerves, tendons, ligaments and joints of the body. There are also sarcomas that grow in the gastrointestinal tract, the long tube running from the oesophagus all the way to the back passage known as Gastrointestinal Stromal Tumours (GISTs), some that grow in the female reproductive system (gynaecological sarcomas) and also some that develop in the areas of the stomach and digestive system (retroperitoneal sarcomas).

For further information on all types of sarcomas please click here

Additional information can also be found by visiting the Sarcoma UK website

   

Trial Spotlight

ICONIC

The purpose of this project is to collect high quality clinical data about patients of all ages with osteosarcoma, such as information about the size of the disease, how it was diagnosed and where it is at diagnosis, what treatments were given and how the disease responded the treatments. We will also collect blood and tissue samples for analysis in research laboratories. By looking at the results of the laboratory findings and the clinical data together, we will start to answer the questions about why osteosarcomas arise and grow, what makes it spread, and why some patients respond to treatment better than others. As time goes on, we plan to use this information to develop clinical trials of new treatments.

This study is recruiting in Royal Aberdeen Children's Hospital. Recruitment currently suspended in Glasgow due to COVID-19

More information on the trial can be found here

 

rEECur

This trial is looking at 4 different types of chemotherapy to treat Ewing’s sarcoma that didn’t respond to initial treatment or has come back afterwards. The aim of the trial is to find out which treatment works best and what has the least side effects. 

This study is recruiting in Royal Aberdeen Children's Hospital. Recruitment currently suspended in Edinburgh and Glasgow due to COVID-19.

For more information about this trial, please click here

 

PK 2013 01

Improved management of cancer patients is anticipated by adjusting treatment of future patients based on differences in drug exposure and expression of biomarkers predictive of response to treatment and toxicity. Although the study focuses on children with Ewing’s sarcoma, the drugs involved in the treatment of this disease and the findings of the study will be applicable across many different types of sarcoma.

Ewing's sarcoma is a bone cancer most commonly diagnosed in teenagers. Current treatment strategies result in approximately 60% of patients being cured but with serious side effects often associated with treatment.

The study is recruiting in Royal Aberdeen Children's Hospital, currently suspended in Edinburgh due to COVID-19.

More information can be found here

 

SSG XXII

A trial for patients taking Imatinib for 3 or 5 years for Gastrointestinal Stromal Tumours (GIST). The most common treatment for patients with this type of rare tumour is to have surgery and then targeted (biological) therapy for 3 years. A type of biological therapy often used is Imatinib (Glivec). It works by blocking a protein called tyrosine kinase that tells cells to divide and grow. Blocking this protein might stop cancer cells from coming back. This study will investigate if it is better to take Imatinib for 5 years instead of 3 as per the usual standard treatment and what are the side effects of doing so.

Recruitment for this study is currently suspended in Glasgow due to COVID-19.

For further information please click here

 

HGUtS

This study is aimed at women who have been diagnosed with sarcoma of the womb (soft tissues of the womb) which has spread or that can’t be treated with surgery. Usually chemotherapy would be recommended as treatment. Doctors are looking at a drug called Cabozantinib, a biological therapy drug, which acts as a cancer growth blocker. It stops signals that cancer cells use to divide and grow. Patients will have chemotherapy followed by either the study drug or a placebo to see if this prevents recurrence of the cancer. They will also study the side effects of using cabozantinib.

The study is recruiting in Glasgow.

Further information can be found here